HIF1A and B-cell chronic lymphocytic leukemia: We also demonstrate that macitentan impairs CLL cells proliferation, interferes with β-catenin signaling and reduces VEGF expression in CLL cells by decreasing hypoxia-inducible factor-1 (HIF-1α) accumulation.